These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 17000863

  • 1. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.
    Braden MR, Parrish JC, Naylor JC, Nichols DE.
    Mol Pharmacol; 2006 Dec; 70(6):1956-64. PubMed ID: 17000863
    [Abstract] [Full Text] [Related]

  • 2. Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists.
    Parrish JC, Braden MR, Gundy E, Nichols DE.
    J Neurochem; 2005 Dec; 95(6):1575-84. PubMed ID: 16277614
    [Abstract] [Full Text] [Related]

  • 3. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
    Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K.
    Synapse; 2000 Feb; 35(2):144-50. PubMed ID: 10611640
    [Abstract] [Full Text] [Related]

  • 4. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ.
    J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
    [Abstract] [Full Text] [Related]

  • 5. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
    Miller KJ, Wu GY, Varnes JG, Levesque P, Li J, Li D, Robl JA, Rossi KA, Wacker DA.
    Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
    Chambers JJ, Parrish JC, Jensen NH, Kurrasch-Orbaugh DM, Marona-Lewicka D, Nichols DE.
    J Med Chem; 2003 Jul 31; 46(16):3526-35. PubMed ID: 12877591
    [Abstract] [Full Text] [Related]

  • 7. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism.
    Kristiansen K, Kroeze WK, Willins DL, Gelber EI, Savage JE, Glennon RA, Roth BL.
    J Pharmacol Exp Ther; 2000 Jun 31; 293(3):735-46. PubMed ID: 10869371
    [Abstract] [Full Text] [Related]

  • 8. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
    Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, Perrone R, Tortorella V.
    J Med Chem; 2004 Dec 16; 47(26):6616-24. PubMed ID: 15588097
    [Abstract] [Full Text] [Related]

  • 9. Single exposure to a serotonin 1A receptor agonist, (+)8-hydroxy-2-(di-n-propylamino)-tetralin, produces a prolonged heterologous desensitization of serotonin 2A receptors in neuroendocrine neurons in vivo.
    Carrasco GA, Van de Kar LD, Jia C, Xu H, Chen Z, Chadda R, Garcia F, Muma NA, Battaglia G.
    J Pharmacol Exp Ther; 2007 Mar 16; 320(3):1078-86. PubMed ID: 17159160
    [Abstract] [Full Text] [Related]

  • 10. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor.
    Braden MR, Nichols DE.
    Mol Pharmacol; 2007 Nov 16; 72(5):1200-9. PubMed ID: 17715398
    [Abstract] [Full Text] [Related]

  • 11. 4-aryl-substituted 2,5-dimethoxyphenethylamines: synthesis and serotonin 5-HT(2A) receptor affinities.
    Trachsel D, Nichols DE, Kidd S, Hadorn M, Baumberger F.
    Chem Biodivers; 2009 May 16; 6(5):692-704. PubMed ID: 19479848
    [Abstract] [Full Text] [Related]

  • 12. A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors.
    Choudhary MS, Craigo S, Roth BL.
    Mol Pharmacol; 1993 May 16; 43(5):755-61. PubMed ID: 8388989
    [Abstract] [Full Text] [Related]

  • 13. Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
    Zajdel P, Subra G, Bojarski AJ, Duszyńska B, Tatarczyńska E, Nikiforuk A, Chojnacka-Wójcik E, Pawłowski M, Martinez J.
    Bioorg Med Chem; 2007 Apr 15; 15(8):2907-19. PubMed ID: 17321139
    [Abstract] [Full Text] [Related]

  • 14. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.
    Blaazer AR, Smid P, Kruse CG.
    ChemMedChem; 2008 Sep 15; 3(9):1299-309. PubMed ID: 18666267
    [Abstract] [Full Text] [Related]

  • 15. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
    Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I.
    Eur J Pharmacol; 2008 Oct 10; 594(1-3):32-8. PubMed ID: 18703043
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and 5-HT(1A), 5-HT(2A) receptor activity of new beta-tetralonohydantoins.
    Byrtus H, Pawłowski M, Czopek A, Bojarski AJ, Duszyńska B, Nowak G, Kłodzińska A, Tatarczyńska E, Wesołowska A, Chojnacka-Wójcik E.
    Eur J Med Chem; 2005 Aug 10; 40(8):820-9. PubMed ID: 16122584
    [Abstract] [Full Text] [Related]

  • 17. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model.
    Roth BL, Choudhary MS, Khan N, Uluer AZ.
    J Pharmacol Exp Ther; 1997 Feb 10; 280(2):576-83. PubMed ID: 9023266
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.
    Görnemann T, Hübner H, Gmeiner P, Horowski R, Latté KP, Flieger M, Pertz HH.
    J Pharmacol Exp Ther; 2008 Mar 10; 324(3):1136-45. PubMed ID: 18096760
    [Abstract] [Full Text] [Related]

  • 19. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
    Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP.
    J Pharmacol Exp Ther; 2007 Jun 10; 321(3):1054-61. PubMed ID: 17337633
    [Abstract] [Full Text] [Related]

  • 20. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
    Monte AP, Marona-Lewicka D, Lewis MM, Mailman RB, Wainscott DB, Nelson DL, Nichols DE.
    J Med Chem; 1998 Jun 04; 41(12):2134-45. PubMed ID: 9622555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.